GNFT News and Press, GENFIT S.A. From 05/11/23

2023-05-11 16:04:46 ET Summary Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029. ...

2023-04-13 16:26:14 ET Genfit press release ( NASDAQ: GNFT ): FY GAAP EPS of -€0.48. Revenue of €26.57M (-69.0% Y/Y). For further details see: Genfit GAAP EPS of -€0.48, revenue of €26.57M

Summary Genfit is a relatively low-beta play offering investors tactical upside with a potential re-rating to the upside. Investors have rewarded the company's pipeline assets to date, in addition to emerging data from its non-invasive technologies. Market generated data is supporti...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developme...

Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...

Genfit press release ( NASDAQ: GNFT ): Q3 Cash and cash equivalents: €163.6 million as of September 30, 2022. Revenue for the first nine months of 2022 amounted to €14,129 thousand compared to €20 thousand for the same period in 2021. Fo...

Genfit press release ( NASDAQ: GNFT ): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27% . For further details see: Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit ( NASDAQ: GNFT ) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused o...

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the...

Gainers: Pliant Therapeutics ( PLRX ) +114% . Kaspien Holdings ( KSPN ) +99% . Iterum Therapeutics ( ITRM ) +83% . La Jolla Pharmaceutical Company ( LJPC ) +81% . Digital World Acquisition ( DWACW ) +51% . Volcon ( VLCN )...